艾昆玮-印度医药市场季度洞察——2024年第一季度（英）

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. Indian Pharmaceutical Market Quarterly Insights – Q1 2024(Jan-Mar)Report Release Date: May 2024Dataset: TSA March 20241DisclaimerIQVIA is not an “authorised person” for the purposes of the Financial Services and Markets Act 2000 (“FSMA”) and does not provide investment advice or carry on any other regulated activity under Part II of the FSMA 2000 (Regulated Activities) Order 2001The forecasts, projections, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third party sources or dataThis report, in part or in whole, is not intended to constitute investment advice, and is not a recommendation to purchase or not purchase, an endorsement of, or an opinion as to the value of, any security or any investment instrument of any entityAs with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks and uncertainties, and are not to be considered guarantees of any particular outcomeThis report shall not be published, nor shall any public references to IQVIA be made regarding these services or this report, without IQVIA’ prior written approval. When so provided, this report and the information herein must always be provided and used in its entirety, including this complete Disclaimer pageThis report is subject to the IQVIA General Terms and Conditions.2Market reflected growth of 6% in Q1 202410%15%10%8%9%6%• Overall IPM market size: ₹216092 Cr. (MAT Mar); ₹ 53,337 Cr (Q1 Mar 2024)• Growth in Sales Value Previous Period Growth (‘PPG’): 8% (MAT); 6% (Q1 2024)• Chronic TAs grew at 10% PPG whereas Acute TAs reflected single digit growth of 3%PPG in Q1 2024• Amongst Chronic TAs, Cardiac registered robust growth of 11% (PPG) and also led in terms of absolute incremental value, followed by Neuro/CNS 8% (PPG), AntiDiabetic 7% (PPG) and Chronic Respiratory 6% (PPG)• Antineoplast, Pain, Uro also registered double digit growth• Anti-infectives reflected degrowth of -2% (PPG). Gastro grew at 5% (PPG) and VMN grew at 7% (PPG)• Respiratory Acute degrew at -9% (PPG)• Pain Acute and Derma grew in single digits. • Relative performance: Indian Pharma Cos grew at 6% (PPG) compared to MNCs which grew at 5% (PPG) for Q1 2024 • Sun, Cipla, Mankind, Intas reflected good growth among Top Indian Pharma Co’s while Abbott, Sanofi, Janssen, Astrazeneca reflected good growths among Top MNC Pharma Co’s • Number of new launches have decreased by -54% in 2024 as compared to 2023MAT Progress, Val ₹ ‘000 Cr.QTR Progress, Val ₹ ’000 Cr.20202021202220232024150157186201216+10%+8%Q4’22Q1’235150Q2’ 23Q3’ 23Q4’ 23Q1’ 245